Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 3,979 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Delirium
Interventions: Dexmedetomidine, Lorazepam; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Opioid-Induced Esophageal Dysfunction
Interventions: Opioid cessation, No opioid cessation; Behavioral · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Pain, Mild Cognitive Impairment
Interventions: Feeling of Being, Health Enhancement Program; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Impairment, Cognitive, Impairment of Attention, Impairment, Psychomotor
Interventions: Delta-9-THC, Delta-8-THC, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 49 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Dyspareunia
Interventions: Estradiol, Imvexxy, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 1,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 42
States / cities: Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more

Conditions: Functional Mitral Regurgitation
Interventions: Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA); Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 99 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Roanoke, Virginia

Conditions: Cancer Survivor, Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: therapeutic testosterone, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 16
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 13 more

Conditions: Psoriasis, Cardiovascular Disease
Interventions: Tildrakizumab; Drug
Lead sponsor: Marcelo F. Di Carli, MD, FACC; Other
Eligibility: 18 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depression
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atopic Dermatitis
Interventions: Nevisense electrical impedance spectroscopy; Device
Lead sponsor: Castle Biosciences Incorporated; Industry
Eligibility: 12 Years to 89 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 16
States / cities: Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 13 more

Conditions: Diastolic Dysfunction, Systolic Dysfunction, Diastolic Heart Failure
Interventions: Sulforaphane; Drug
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 60 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Aging, Blood Pressure, Endothelial Dysfunction, Hypertension
Interventions: High-resistance inspiratory muscle strength training, Aerobic exercise; Other
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 50 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Spinal Cord Injuries, Neurogenic Lower Urinary Tract Dysfunction, Neurogenic Bladder
Interventions: Not listed
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Friedreich Ataxia
Interventions: Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg, Placebo, Omaveloxolone Capsules, 20 mg, Omaveloxolone Capsules, 40 mg, Omaveloxolone Capsules, 80 mg, Omaveloxolone Capsules, 160 mg, Omaveloxolone Capsules, 300 mg, Omaveloxolone Capsules, 150 mg; Drug
Lead sponsor: Biogen; Industry
Eligibility: 16 Years to 40 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 7
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 4 more

Conditions: Alzheimer's Disease
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: North Coast Medical Activadose II; Device
Lead sponsor: The Mind Research Network; Other
Eligibility: 50 Years to 90 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Alzheimer Disease, Cognition Disorders
Interventions: Rivastigmine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 15
States / cities: Peoria, Arizona • Orange, California • Denver, Colorado + 12 more

Conditions: Myocardial Reperfusion Injury
Interventions: BQ-123, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Executive Dysfunction, Depression
Interventions: Intermittent Theta Burst Stimulation, sham stimulation; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years to 85 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Penile Injection Therapy, Erectile Dysfunction, Radical Pelvic Surgery
Interventions: Questionnaires.; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Male only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Placebo, RO4917838, Standard Antipsychotic Therapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Orangeburg, New York

Conditions: Congestive Heart Failure, Heart Failure, Diastolic
Interventions: Allogeneic Derived Cells, Placebo/Control Arm; Biological
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 50 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions: Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS); Diagnostic Test
Lead sponsor: PharmaNest, Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 1,519 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status

Effect of Opioid Cessation on Opioid-Induced Esophageal Dysfunction

Mindfulness-Based Cognitive Therapy Vs. the Health Enhancement Program for Chronic Pain and Early Cognitive Decline; The Feeling of Being Pilot RCT

High Confusion: Cannabis & Driving

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

MIcrovascular dysfuNction In Moderate-severe Psoriasis

Platelet Function in Patients Treated With SSRI and Non-SSRI Antidepressants

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Inspiratory Muscle Strength Training for Lowering Blood Pressure and Improving Endothelial Function in Postmenopausal Women: Comparison With "Standard of Care" Aerobic Exercise

Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms

A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia

Brain Aging Project--Kansas University

Enhancing Memory in Mild Cognitive Impairment and Early Stage Alzheimer's Disease

Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

iTBS Study for Depression (Randomized)

Penile Injection Anxiety

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs

Digital Pathology and AI for Liver Outcomes in MASLD (DPAILO-2)